Christopher Starr
Founder at MONOPAR THERAPEUTICS INC.
Net worth: 45 986 $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kim Tsuchimoto | F | 61 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007.
Glyko, Inc.
 Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | 27 years |
| Raymond Anderson | M | 82 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 20 years |
| Patrice Rioux | M | 73 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 14 years |
| Gregg Lapointe | M | 65 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 10 years |
| Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 13 years |
| Chandler Robinson | M | 40 | 10 years | |
| Brook Riggins | M | 58 | - | |
| Peter C. M. McWilliams | M | - |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Michael Brown | M | 67 | 10 years | |
| W. Mullally | M | 50 | 6 years | |
| Steven Jon Axon | M | 49 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Kim Lee | M | - | 10 years | |
| Paul Hoelscher | M | 59 | 8 years | |
| Arthur Klausner | M | 64 | 7 years | |
| Brian Mueller | M | 50 | 22 years | |
| Elaine Heron | M | 76 | 22 years | |
| George Davis | M | 53 | 20 years | |
| Andrew Cittadine | M | 52 | 3 years | |
| Niall O'Donnell | M | 51 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Ken Harrison | M | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Kenneth Harrison | M | 44 |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Jim Trenkle | M | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Laura Kelly | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 years |
| Julie Smith | F | 53 | - | |
| Erich Sager | M | 66 | 16 years | |
| Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 6 years |
| Todd C. Zankel | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 12 years |
| Jean-Jacques Bienaimé | M | 70 | 19 years | |
| Michael Patrick Smith | M | 55 | 1 years | |
| Jeff Ajer | M | 61 | 19 years | |
| Grant W. Denison | M | - | - | |
| Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 years |
| Agnes Rafalko | M | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | - |
| Andrew Mazar | M | 62 | 8 years | |
| Pierre LaPalme | M | 83 | 12 years | |
| Llew Keltner | M | 74 | 7 years | |
| Ashley C. Gould | F | 49 | - | |
| Rick Franklin | M | 78 | 7 years | |
| Michael Grey | M | 71 | 16 years | |
| Mark Wood | M | 57 | 9 years | |
| Joshua Grass | M | - | 14 years | |
| Alan J. Lewis | M | 78 | 15 years | |
| Craig Johnson | M | 62 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 1 years |
| Fredric D. Price | M | 78 | 4 years | |
| Louis C. Drapeau | M | 79 | 3 years | |
| Sandra Shpilberg | F | 48 | 9 years | |
| Frank Lanza | M | 62 | - | |
| Georges Gemayel | M | 63 | 1 years | |
| Paul K. Ross | M | - | - | |
| Patricia Donahue | F | - | - | |
| Michael DesJardin | M | 66 | 1 years | |
| Karl Cahill | M | 51 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | - |
| John Ditton | M | 60 | 2 years | |
| Krishna R. Polu | M | 50 | 1 years | |
| R. Ramelmeier | M | 62 | 8 years | |
| Min MIn Qin | M | 66 | 7 years | |
| Dan Oppenheimer | M | - | 14 years | |
| Justin Ford | M | - | - | |
| Vimal Srivastava | M | 58 | 2 years | |
| Henk Doude van Troostwijk | M | - | - | |
| Alejandro Dorenbaum | M | 64 | 7 years | |
| Christine Murray | F | 63 | 2 years | |
| John Urquhart | M | - | - | |
| Amy Lea Waterhouse | F | - | - | |
| Stephen Aselage | M | 73 | 7 years | |
| Jeffrey Cooper | M | 68 | 9 years | |
| Thomas E. Daley | M | 61 | 6 years | |
| David Scott Geyer | M | 65 | 1 years | |
| Marc Patrick Reichenberger | M | 59 | - | |
| Joseph Klein | M | 62 | 5 years | |
| Ansbert Gadicke | M | 66 | 4 years | |
| John C. Klock | M | 79 | - | |
| Emil Kakkis | M | 63 | 11 years | |
| John Hamilton | M | 79 |
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | 4 years |
| Bill Aliski | M | 75 | 3 years | |
| Robert Baffi | M | 68 | 20 years | |
| Stuart J. Swiedler | M | 68 | - | |
| Franz L. Cristiani | M | 83 | - | |
| Matt Patterson | M | 52 | 6 years | |
| Robert A. Heft | M | 69 | 3 years | |
| Brett Scott | M | 73 | - | |
| David Happel | M | 62 | 2 years | |
| Steven Jungles | M | 58 | - | |
| Octávio Costa | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 83 | 97.65% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher Starr
- Personal Network